ETH-CAT
N-ethylcathinone
Viewing r1 — May 11, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
ETH-CAT (N-ethylcathinone) is a synthetic stimulant of the cathinone class. It is the active metabolite of diethylpropion, a prescription appetite suppressant used since the 1950s. It floods the brain with norepinephrine — the body's arousal chemical — while only weakly engaging the dopamine reward system.[1]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
Ethcathinone occurs naturally in khat[2] and had been produced inside the bodies of patients taking diethylpropion for decades before anyone studied it independently.[3] It first appeared as a recreational drug in 2007, sold in Australian party pill capsules alongside mephedrone.[4] It is now controlled in most countries and rarely encountered in forensic casework.
Subjective effects include stimulation, wakefulness, appetite suppression, mild mood lift, and restless physical energy. The experience is energizing rather than euphoric — a noradrenergic push that delivers alertness more than pleasure, lighter on reward than more potent cathinones.[5] Anxiety, compulsive urges to redose, and a draining comedown are the characteristic unwanted effects.
Physical dependence has not been established, but compulsive redosing is common; the primary acute danger is cardiovascular — norepinephrine raises heart rate and blood pressure in proportion to dose.[1] Risk is greatest when combined with other substances, especially those that also act on serotonin or the cardiovascular system.[6] There are no controlled human studies — understanding rests on one case report, class-level cathinone data, and community experience.
History[edit]
Discovery
Ethcathinone is a natural component of khat[2] and the active metabolite of diethylpropion, a prescription appetite suppressant sold since the 1950s. In 1987, researchers showed that the liver converts diethylpropion into ethcathinone — accounting for roughly 35% of the dose — making it the compound responsible for the drug's stimulant and appetite-suppressing effects.[3] Millions of patients had been producing it internally for decades before it was studied as a standalone compound.
Recreational emergence
Ethcathinone first appeared as a recreational product in August 2007, when capsules from an Israeli internet company were chemically identified in South Australia as containing both ethcathinone and mephedrone — one of the earliest published detections of either compound in consumer products.[4] Denmark banned it in December 2008, and the UK enacted a blanket cathinone ban in 2010.
Current status
ETH-CAT is now rare in forensic casework. The UK's drug advisory body recorded only 20 detections from 2020–2023.[7] In 2026, it was found in UK school-confiscated vapes sold as THC products — an uncontrolled exposure route with particular relevance for young people.[8]
The name ethcathinone reflects its structure: an N-ethyl substitution on cathinone, the principal stimulant alkaloid of khat. The abbreviation ETH-CAT follows the same naming pattern as METH-CAT (methcathinone). The compound has an unusual dual identity — millions of patients have produced it internally through prescribed diethylpropion, while the same molecule circulates independently as a controlled recreational drug.
Chemistry[edit]
Structural class
ETH-CAT belongs to the substituted cathinone family — a group of amphetamine-like compounds sharing a phenyl ring and an amino ketone backbone. It differs from the parent compound cathinone by a single N-ethyl group on the nitrogen; compared to methcathinone, it has one additional carbon at the same position.[9]
This small structural change shifts its pharmacological profile away from dopamine dominance toward norepinephrine and serotonin. Its molecular formula is C₁₁H₁₅NO (177.24 g/mol), and it occurs naturally in Catha edulis (khat).[2]
ETH-CAT is also the active metabolite of diethylpropion, a prescription appetite suppressant. The liver removes one ethyl group from diethylpropion to produce ethcathinone, accounting for roughly 35% of the administered dose.[3] Commercially encountered material is racemic mixture — it contains both mirror-image forms of the molecule in equal measure.[10]
Pharmacology[edit]
Mechanism of action
ETH-CAT forces norepinephrine out of nerve terminals, flooding the brain's arousal circuits.[1] It also releases serotonin but does not release dopamine — instead it weakly blocks the DAT without triggering dopamine efflux.[5] This combination is atypical for a cathinone;[11] adding one extra carbon to the nitrogen chain is what shifts the profile away from dopamine dominance.[9]
Prodrug relationship
ETH-CAT is the active metabolite of diethylpropion, a licensed appetite suppressant. Diethylpropion itself has no direct transporter activity — the liver strips one ethyl group to produce ethcathinone, which accounts for roughly 35% of the administered dose.[3] Sustained-release formulations maintain plateau ethcathinone levels in the blood for 6–8 hours.[12]
Pharmacokinetics
No pharmacokinetic data exist for ethcathinone administered directly to humans. Genetic variation in liver enzymes significantly affects how much ethcathinone is produced from diethylpropion — four distinct metabolizer types have been identified in a study of healthy volunteers,[13] implying substantial person-to-person variability in effects and duration. Reported onset, peak, and duration times come from community experience, not published pharmacokinetic studies. safety citation needed
Neuroscience[edit]
Where it acts
ETH-CAT's norepinephrine release activates the brain's arousal system, sending activation signals across the cortex, thalamus, and amygdala.[1] Weak dopamine blockade gives some engagement of the mesolimbic pathway — enough for mild pleasure, but far less than dopamine-releasing cathinones like mephedrone.[11] Serotonin release adds a subtle mood lift[5] and may also drive the dangerous sodium loss seen in the published clinical case.[6]
Why it matters
ETH-CAT creates motivational urgency through noradrenaline while providing limited dopamine reward — the compulsive redosing urge outpaces the satisfaction each dose delivers. With repeated use, cathinones cause the brain's transporter proteins to downregulate, blunting effects over time.[14] Whether ethcathinone specifically produces tolerance or behavioral sensitization has not been studied.
The magnitude of ethcathinone's serotonin release is unquantified — at what dose does it become clinically significant? No data exist on whether chronic use produces neurotoxicity, though synthetic cathinones as a class show neurotoxic potential in animal models.[15] The pharmacological activity of individual enantiomers remains unexplored.
Subjective Effects[edit]
ETH-CAT produces a stimulant experience built on physical arousal rather than pleasure. The result is energizing and wakeful — appetite drops, attention sharpens, and movement feels natural — but the hedonic pull is modest. Whether that energy reads as productive focus or anxious agitation depends heavily on the setting and the person's state.
Compared to mephedrone, ethcathinone is less euphoric and less empathogenic, consistent with its weaker dopamine and serotonin activity. Relative to amphetamine, it occupies a lower-potency, shorter-duration position — edgier in character and less suited to sustained focus.
Effect Grid
Clear stimulant effects emerge — pronounced stimulation, sustained wakefulness, and noticeable appetite suppression. Cognitive euphoria and focus enhancement become apparent. Thought acceleration produces a sense of mental sharpness and increased motivation.
Sympathomimetic activation is more prominent: elevated heart rate, potential bruxism, and mild dehydration sensation. Some tactile euphoria may be present. The compulsive redosing urge may emerge, particularly with insufflated administration where the shorter duration intensifies the drive to re-dose.
Insomnia is likely if taken within 4–5 hours of intended sleep. The overall character is more "functional stimulation" than euphoric rush, reflecting ethcathinone's NET-preferential profile with weak dopaminergic reward.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Tinnitus · Visual haze / noise
Pupil dilation · Dry mouth · Insomnia · Physical fatigue · Restlessness · Dehydration sensation · Body high · Excessive sweating · Heart rate perception changes · Muscle tension · Bruxism · Breathing alteration · Headache · Nasal congestion · Nausea · Sexual arousal enhancement · Tactile euphoria · Dizziness · Respiratory stimulation · Trembling · Motor control impairment
Physical fatigue · Restlessness · Dehydration sensation · Body high · Excessive sweating · Heart rate perception changes · Muscle tension · Bruxism · Breathing alteration · Headache · Nasal congestion · Nausea · Sexual arousal enhancement · Tactile euphoria · Dizziness · Respiratory stimulation · Trembling
Focus enhancement · Motivation enhancement · Motivation suppression · Immersion enhancement · Information processing enhancement · Thought organization · Analysis enhancement · Thought deceleration · Cognitive dysphoria · Cognitive flexibility · Cognitive impairment · Pattern recognition enhancement · Language enhancement · Memory enhancement · Confusion · Thought disorganization
Information processing enhancement · Thought organization · Analysis enhancement · Thought deceleration · Cognitive dysphoria · Cognitive flexibility · Cognitive impairment · Pattern recognition enhancement · Language enhancement · Memory enhancement · Confusion · Thought disorganization
Anhedonia · Dysphoria
Ego inflation · Sociability enhancement · Social connection · Flow state · Depersonalization · Derealization
Depersonalization · Derealization
Timeline
Gradual awareness of stimulant effects emerges — subtle increase in heart rate and alertness. Most users notice a faint shift in baseline arousal before distinct effects manifest.
Stimulation builds steadily. Mood elevation emerges, appetite suppression begins, and noradrenergic arousal becomes unmistakable. Heart rate and blood pressure rise noticeably.
Full stimulant effect — maximum alertness, cognitive euphoria, and sympathomimetic activation. Focus enhancement and thought acceleration are most pronounced. Compulsive redosing urge may emerge.
Gradual decline in stimulation. Cognitive fatigue begins to replace focus enhancement. Residual wakefulness persists while mood and motivation drop.
Residual wakefulness and possible irritability. Appetite slowly returns. Cognitive fatigue and low mood may linger.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- Low
- Withdrawal
- Mild
- Tolerance buildup
- moderate
- Tolerance reset
- 4 days
- Physical
- Negligible
- Psychological
- Low
- Compulsive redosing
- Moderate
- Dose escalation
- Low
- Cross-tol.
- dopamine · stimulant
Toxicity
Acute toxicity
The only published case report involved a 22-year-old woman who took ethcathinone alongside methylone and alcohol.[6] She developed seizures, dangerously low sodium (Na⁺ = 120 mmol/L), and severe muscle breakdown (CK = 34,537 U/L), and survived after a 6-day hospitalization. Because multiple substances were involved, ethcathinone's individual contribution cannot be determined.
Cardiovascular toxicity
Ethcathinone releases norepinephrine — a stress hormone — which directly raises heart rate and blood pressure. For synthetic cathinones as a class, documented cardiovascular risks include rapid heart rate, high blood pressure, abnormal rhythms, chest pain, and rare cases of heart attack, stroke, and cardiac arrest.[7] No ethcathinone-specific cardiovascular data exist. inferred
Metabolic and systemic toxicity
Class-level cathinone risks include dangerously elevated body temperature, metabolic acidosis, muscle breakdown, and kidney failure.[16] The severe muscle breakdown seen in the clinical case report aligns with this pattern.[6]
Forensic detections
ETH-CAT appears rarely in forensic casework. Polish data found it in 5 of 112 novel psychoactive substance cases,[17] and it has appeared in postmortem hair analysis alongside up to eight other cathinones.[18] The UK drug advisory body recorded only 20 detections from 2020–2023 and noted it is "infrequently implicated as cause of death".[7] In 2026, it was found in UK school-confiscated vapes sold as THC products.[8]
Psychological risks
No controlled data on ethcathinone's psychological risks exist. For synthetic cathinones as a class:
- Acute effects can include agitation, confusion, paranoia, hallucinations, and delirium.[19]
- Neurological emergencies including brain swelling, coma, convulsions, and serotonin syndrome — a dangerous overheating and seizure response — have been documented.[15]
- Chronic use can trigger psychosis, hypomania, and delusional thinking.[19]
The seizure in the clinical case report was attributed to sodium depletion rather than direct neurotoxicity,[6] but a direct effect on seizure threshold at high doses cannot be excluded.
Tolerance and dependence
Tolerance
Synthetic cathinones develop tolerance through transporter downregulation and receptor desensitization.[14] No ethcathinone-specific tolerance data have been published. safety citation needed
Dependence
Cathinones as a class have rewarding properties confirmed in animal studies.[20] Brain reward studies with a close structural analog show activation at lower potency than methamphetamine,[21] suggesting moderate rather than high reinforcement. Ethcathinone's weak dopamine activity predicts lower abuse liability than dopamine-releasing cathinones — stimulant reinforcement tracks primarily with dopamine release magnitude.[11]
Withdrawal
No withdrawal data exist for ethcathinone. Cathinone class withdrawal is primarily psychological: fatigue, low mood, craving, and difficulty feeling pleasure. Physical symptoms are generally mild or absent.
Drug interactions
Tramadol
Classified as lethal. Tramadol blocks serotonin and norepinephrine reuptake, releases serotonin, and lowers the seizure threshold. Combined with ethcathinone's norepinephrine and serotonin release, the mixture creates additive risk of serotonin syndrome, seizures, and cardiovascular collapse.[22] safety citation needed
MDMA
Classified as dangerous. Both compounds release serotonin. Together they sharply raise the risk of serotonin syndrome — a life-threatening overheating and seizure response[23] — along with dangerously low sodium[6] and cardiovascular overload. safety citation needed
Alcohol
Classified as unknown. No published data on this combination exist. Alcohol was present in the sole clinical case report alongside ethcathinone and methylone,[6] but its contribution to toxicity was not analyzed.
MAOIs
Monoamine oxidase inhibitors block the breakdown of noradrenaline and serotonin in the brain. Combined with ethcathinone's release of both, this creates risk of dangerously high blood pressure or serotonin syndrome — a class-level contraindication for all monoamine-releasing stimulants.[24] safety citation needed
Multiple substance co-ingestion
Taking multiple novel psychoactive substances together — the most common real-world pattern among cathinone users — is the highest-risk scenario.[24] ETH-CAT is consistently found alongside other cathinones and conventional drugs in forensic casework.[17][18]
Contraindications
- Heart disease or high blood pressure (absolute): Ethcathinone's norepinephrine release directly raises heart rate, blood pressure, and cardiac workload.
- Seizure disorder (absolute): Seizures have been documented in the context of ethcathinone ingestion.[6]
- Concurrent MAOI use (absolute): Risk of dangerously high blood pressure and serotonin syndrome.
- Concurrent serotonergic drugs (relative): SSRIs, SNRIs, tramadol, and MDMA increase serotonin syndrome risk.
- Liver impairment (relative): Impaired liver clearance[13] may prolong and intensify effects.
- Pregnancy (absolute): No reproductive data exist. Contraindicated by precautionary principle.
- History of psychosis, mania, or severe anxiety (relative): Cathinone use can trigger psychosis, hypomania, and paranoid thinking.[19]
Harm Reduction[edit]
Forms & Identification
ETH-CAT typically appears as a white crystalline powder or in capsules. It is visually indistinguishable from dozens of other cathinone powders, and standard laboratory gas chromatography can produce misleading degradation artifacts that complicate identification.[25] Any powder sold as ethcathinone should be verified through a drug checking service before use.
In 2026, ethcathinone was found in UK school-confiscated vapes marketed as THC products.[8] Testing is especially critical when the source or labeling is uncertain.
Guidelines
- Test all material with a reagent kit and, where possible, a drug checking service before use.
- Start with the lowest reported active dose and wait at least 90 minutes before considering redosing — compulsive redosing is a consistently reported pattern with this compound.
- Stay hydrated but do not overdrink. The clinical case report documented dangerous sodium depletion linked in part to excessive water intake (3.5 L).[6]
- Monitor heart rate if possible. Persistent rapid heart rate, chest pain, or irregular heartbeat warrants stopping activity and seeking medical evaluation.
- Avoid insufflation where possible — it produces more intense effects with shorter duration and reportedly intensifies compulsive redosing.
- Eat a meal before use to support sustained energy and reduce post-experience crashes.
- Have a sober companion present, particularly at higher doses or with unfamiliar material.
Set & Setting
ETH-CAT's norepinephrine-driven arousal can tip toward restlessness and paranoia in anxious or unfamiliar settings. A calm, familiar environment with trusted company reduces the likelihood of anxiety escalating.
Avoid use when sleep-deprived or dehydrated — both amplify cardiovascular strain. Settings where physical movement is natural are more manageable than confined, sedentary environments.
Aftercare & integration. The comedown from ethcathinone brings fatigue, low mood, and difficulty sleeping as noradrenaline reserves recover. Prioritize sleep in a dark, quiet room and avoid further stimulants including caffeine. Eat a full meal even if appetite remains suppressed — complex carbohydrates and protein support neurotransmitter recovery.
If anxiety, paranoia, or low mood persist beyond 48 hours, or if compulsive redosing occurred during the session, consider speaking with a healthcare provider or harm reduction service.
Recovery & Support
ETH-CAT's compulsive redosing pattern can escalate to habitual use. If use is becoming more frequent, doses are increasing, or cravings persist between sessions, professional support is warranted. Stimulant-specific treatment programs, cognitive behavioral therapy, and peer support groups such as SMART Recovery can help. A healthcare provider can assess whether underlying conditions are contributing to use patterns.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Chest pain, seizures, loss of consciousness, body temperature hot to the touch through clothing, confusion or agitation severe enough to prevent communication, or blue-grey discoloration of lips or fingertips.
Immediate steps:
- 1. Call emergency services immediately if any of the above signs are present.
- 2. Place an unconscious but breathing person in the recovery position (on their side, airway clear).
- 3. If body temperature is dangerously high, move to a cool area and apply cool (not ice-cold) water to skin.
- 4. Do not restrain an agitated person unless they pose immediate danger to themselves or others.
- 5. Do not induce vomiting.
What to tell the dispatcher: The substance taken (ethcathinone or synthetic cathinone), the amount if known, the time of ingestion, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
No reversal agent exists for cathinone stimulant overdose. Treatment is supportive.
Legal Status[edit]
Ethcathinone is controlled in most major jurisdictions, typically under generic cathinone provisions rather than substance-specific scheduling.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Not specifically scheduled; Federal Analogue Act applicable | Enforceable as a cathinone analog when intended for human consumption. Exact federal scheduling status requires DEA confirmation. citation needed |
| United Kingdom | Class B, Schedule 1 (Misuse of Drugs Act 1971) | Controlled under generic cathinone clause enacted in 2010; reinforced by the Psychoactive Substances Act 2016[7] |
| Germany | Anlage II BtMG (Schedule II) | Controlled since July 26, 2012. No authorized trade without license[26] |
| Denmark | Banned | Controlled since December 18, 2008 — one of the earliest national bans on a synthetic cathinone[26] |
| Poland | Group I-P controlled substance | Controlled; ethcathinone detected in forensic casework from 2012 onward[17] |
| China | Controlled substance | Controlled since October 2015[26] |
| Brazil | F2 classification | Listed under controlled substance provisions[26] |
| Australia | Controlled substance | Listed by the Office of Drug Control. Specific schedule not confirmed. citation needed |
| Canada | Likely covered under cathinone catch-all or analog provisions | No specific schedule confirmation found. citation needed |
Analog and prodrug considerations
Diethylpropion remains a licensed medicine in several countries, while ethcathinone — the metabolite it produces in the body — is itself a controlled substance when sold independently. This regulatory asymmetry has not been explicitly addressed in published regulatory analyses.
Legal status changes over time and varies by jurisdiction. This information is not legal advice — verify current status with the relevant authority before relying on it.
references
- [1]
- [2] ^abcShi HF, Xu BP, Xu CX, Zhou XQ, Xu HF (2023) Rapid extraction and detection of five alkaloids in dried khat by solvent extraction-HPLC-Q-TOF-MS — Se Pu (Chinese Journal of Chromatography) doi:10.3724/sp.j.1123.2023.03009
- [3] ^abcdBeckett AH, Stanojcić M (1987) Re-evaluation of the metabolism and excretion of diethylpropion in non-sustained and sustained release formulations — Journal of Pharmacy and Pharmacology PMID:2886596
- [4] ^abCamilleri A, Johnston MR, Brennan M, Davis S, Caldicott DG (2010) Chemical analysis of four capsules containing the controlled substance analogues 4-methylmethcathinone, 2-fluoromethamphetamine, alpha-phthalimidopropiophenone and N-ethylcathinone — Forensic Science International doi:10.1016/j.forsciint.2009.12.048
- [5] ^abcNadal-Gratacós N, Pazos MD, Pubill D, Camarasa J, Escubedo E, Berzosa X, López-Arnau R (2024) Structure-Activity Relationship of Synthetic Cathinones: An Updated Review — ACS Pharmacology and Translational Science doi:10.1021/acsptsci.4c00299
- [6]